Anatomy & Physiology: Current Research
Open Access

Abstract

Efficacy of Etoposide Against Doxorubicin Induced Cardiotoxicity in H9c2 Cardiomyoblasts

Sara Shabana*

Doxorubicin (DOX), a broadly utilized anticancer medication, has been related with cardiotoxicity. As of late, DOX-prompted cardiotoxicity has been ascribed to topoisomerase II (TOPII)-β articulation and movement. In our examination, we researched the impact of restraining TOPII in weakening the DOX actuated cardiotoxicity. H9c2 cardiomyoblasts were treated with 1 or 2 μM DOX ETO. Cardiotoxicity was surveyed by inspecting cell reasonability utilizing the MTT measure, hypertrophy of gem violet recolored cardiomyoblasts and ROS creation. DOX instigated a portion subordinate expansion in cardiotoxicity as demonstrated by the huge decrease in cell suitability DOX versus 100% control.

Published Date: 2022-09-01; Received Date: 2022-08-01